Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals
Richard DiCicco co-founded Harvest Moon Pharmaceuticals USA, Inc. in 2007 with a proven pipeline of complex generic products developed since 1984 (CV Richard Dicicco, APR 2, 2014, View Source [SID:1234501869]). Harvest Moon Pharma develops, manufactures sells and/or licenses-out to the trade, worldwide, these complex generic drug products and biosimilars. After seeking scientific advice from the EMA, Harvest Moon Pharma has biosimilars of adalimumab, rituximab and trastuzumab entering phase I clinical trials in Europe. These mAbs were developed in Europe with comparability studies to both the European and USA reference listed biological, are produced in the USA, and comply with the EMA mAb adopted and revised guidelines. They will be filed in Europe and the USA in 2016. Harvest Moon Pharma offers etanercept, infliximab and bevacizumab which will be filed in Europe and the USA in 2017. Mr. DiCicco is a member of the Editorial Board of the Journal of Generic Medicines, a member of the Licensing Executives Society, speaks often and is widely published in generics, biosimilars and the emerging markets of MENA, APAC and BRICKTM.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!